PEDIATRIC PALLIATIVE CARE DRUGS MARKET ANALYSIS

Regional Analysis

Global Pediatric Palliative Care Drugs Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global pediatric palliative care drugs market over the forecast period owing to increasing launches of products. For instance, on September 12, 2022, the U.S. FDA announced the approval of Atezolizumab [Tecentriq], as a single agent, for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). The approval was given to Genentech, Inc., a U.S.-based biotechnology corporation.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa